Pathfinders in Biopharma

46 Episodes

1. Uncertainty reigns, but opportunity persists for biotech’s 2025

   Published: 2/7/2025
2. Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments

   Published: 11/22/2024
3. Former Investor Who Chose Broadcasting Over Biotech ETFs

   Published: 9/30/2024
4. Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?

   Published: 8/29/2024
5. Shots-on-Goal Licensing Company Aims for Breakthroughs

   Published: 7/19/2024
6. Why Biopharma Needs to Tell Better Stories on Novel Drugs

   Published: 7/11/2024
7. Venture capital velocity: What’s driving renewed momentum in biotech?

   Published: 7/8/2024
8. Pharma Understands Phase One Data – But Does the Market?

   Published: 6/21/2024
9. Davern Capital sees GLP-1 Opportunities Beyond Obesity

   Published: 6/14/2024
10. Betting on Healthcare’s Future Hits – and Misses

    Published: 6/10/2024
11. Innovation and an Aging Population Drive MedTech

    Published: 6/5/2024
12. Biopharma Investors See Opportunities in Targeted Treatments and Gene Editing

    Published: 6/3/2024
13. Biotech with a Mission to Target Unmet Cancer Needs

    Published: 5/31/2024
14. The M&A Pool Set to Accelerate Biotech Innovation

    Published: 4/3/2024
15. How PIPEs finally unblocked biotech’s funding flows

    Published: 3/29/2024
16. Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back

    Published: 3/7/2024
17. Will the Biotech Rebound Run into Pricing Policy Obstacles?

    Published: 2/27/2024
18. Few IPOs but plenty of follow-on for biotech in 2023

    Published: 1/22/2024
19. U.S. Outlook: Will the US economy achieve a soft landing in 2024?

    Published: 12/29/2023
20. Raising Venture Capital: A New Playbook for A New Era in Biotech

    Published: 11/22/2023